{"name":"Supernus Pharmaceuticals","slug":"supernus","ticker":"SUPN","exchange":"NASDAQ","domain":"supernus.com","description":"Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervica","hq":"Rockville, MD, USA","founded":0,"employees":"778","ceo":"Jack A. Khattar","sector":"CNS / Neuroscience","stockPrice":51.13,"stockChange":-0.23,"stockChangePercent":-0.45,"marketCap":"$3.0B","metrics":{"revenue":776833024,"revenueGrowth":38.6,"grossMargin":74.1,"rdSpend":106235000,"netIncome":-38550000,"cash":384240992,"dividendYield":0,"peRatio":11.7,"fiscalYear":"FY2019"},"revenueBreakdown":[],"timeline":[{"date":"2019-01-01","label":"ZULRESSO® first approved","drug":"ZULRESSO®","drugSlug":"zulresso","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Oxtellar XR patent cliff ($143.8M at risk)","drug":"Oxtellar XR","type":"patent_expiry","sentiment":"negative"},{"date":"2035-06-01","label":"Trokendi XR patent cliff ($64.4M at risk)","drug":"Trokendi XR","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"SPN-810 (18 mg)","genericName":"SPN-810 (18 mg)","slug":"spn-810-18-mg","indication":"Attention-deficit/hyperactivity disorder (ADHD) with impulsivity in adults","status":"phase_3"},{"name":"Oxcarbazepine XR","genericName":"Oxcarbazepine XR","slug":"oxcarbazepine-xr","indication":"Partial-onset seizures (monotherapy and adjunctive therapy)","status":"phase_3"},{"name":"SAGE-547","genericName":"SAGE-547","slug":"sage-547","indication":"Status epilepticus","status":"phase_3"},{"name":"SPN-812 (600mg, QD)","genericName":"SPN-812 (600mg, QD)","slug":"spn-812-600mg-qd","indication":"Attention-deficit/hyperactivity disorder (ADHD) in children and adolescents","status":"marketed"},{"name":"ZULRESSO®","genericName":"ZULRESSO®","slug":"zulresso","indication":"Postpartum depression","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"immunology","drugs":[{"name":"SPN-810 (36 mg)","genericName":"SPN-810 (36 mg)","slug":"spn-810-36-mg","indication":"Disruptive mood dysregulation disorder (DMDD)","status":"phase_3"},{"name":"SPN-812","genericName":"SPN-812","slug":"spn-812","indication":"Other","status":"marketed"},{"name":"MYOBLOC","genericName":"MYOBLOC","slug":"myobloc","indication":"Cervical dystonia (torticollis)","status":"marketed"},{"name":"SPN-538","genericName":"SPN-538","slug":"spn-538","indication":"Other","status":"marketed"},{"name":"SPN-817, Treatment B","genericName":"SPN-817, Treatment B","slug":"spn-817-treatment-b","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"SPN-810 (18 mg)","genericName":"SPN-810 (18 mg)","slug":"spn-810-18-mg","phase":"phase_3","mechanism":"SPN-810 is a selective serotonin 5-HT1A receptor agonist that modulates serotonergic neurotransmission to reduce impulsivity and improve behavioral control.","indications":["Attention-deficit/hyperactivity disorder (ADHD) with impulsivity in adults"],"catalyst":""},{"name":"SPN-810 (36 mg)","genericName":"SPN-810 (36 mg)","slug":"spn-810-36-mg","phase":"phase_3","mechanism":"SPN-810 is a proprietary formulation of a divalproex sodium extended-release product designed to treat disruptive mood dysregulation disorder (DMDD).","indications":["Disruptive mood dysregulation disorder (DMDD)"],"catalyst":""},{"name":"SPN-812","genericName":"SPN-812","slug":"spn-812","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"MYOBLOC","genericName":"MYOBLOC","slug":"myobloc","phase":"marketed","mechanism":"MYOBLOC is a botulinum toxin type B that blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins.","indications":["Cervical dystonia (torticollis)","Blepharospasm","Strabismus"],"catalyst":""},{"name":"Oxcarbazepine XR","genericName":"Oxcarbazepine XR","slug":"oxcarbazepine-xr","phase":"phase_3","mechanism":"Oxcarbazepine XR is an extended-release anticonvulsant that blocks voltage-gated sodium channels to reduce neuronal excitability and prevent seizures.","indications":["Partial-onset seizures (monotherapy and adjunctive therapy)","Generalized tonic-clonic seizures (adjunctive therapy)"],"catalyst":""},{"name":"SAGE-547","genericName":"SAGE-547","slug":"sage-547","phase":"phase_3","mechanism":"SAGE-547 is an intravenous formulation of an antisense oligonucleotide that targets the GABA_A receptor alpha 1 subunit.","indications":["Status epilepticus"],"catalyst":""},{"name":"SPN-538","genericName":"SPN-538","slug":"spn-538","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"SPN-812 (600mg, QD)","genericName":"SPN-812 (600mg, QD)","slug":"spn-812-600mg-qd","phase":"marketed","mechanism":"SPN-812 is a selective norepinephrine reuptake inhibitor that increases norepinephrine availability in the central nervous system to improve attention and executive function.","indications":["Attention-deficit/hyperactivity disorder (ADHD) in children and adolescents"],"catalyst":""},{"name":"SPN-817, Treatment B","genericName":"SPN-817, Treatment B","slug":"spn-817-treatment-b","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ZULRESSO®","genericName":"ZULRESSO®","slug":"zulresso","phase":"marketed","mechanism":"GABA-A receptor alpha-1/beta-2/gamma-2","indications":["Postpartum depression"],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"earnings","headline":"Supernus Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Supernus Pharmaceuticals reported its financial results for the fourth quarter and full year 2023, with revenue of $244.4 million and a net loss of $14.4 million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"Supernus Pharmaceuticals Announces Exclusive Licensing Agreement with a Leading Pharmaceutical Company","summary":"Supernus Pharmaceuticals announced an exclusive licensing agreement with a leading pharmaceutical company to develop and commercialize a new product for the treatment of a CNS disorder.","drugName":"","sentiment":"positive"},{"date":"2023-08-14","type":"regulatory","headline":"Supernus Pharmaceuticals Receives FDA Approval for New Indication for Oxtellar XR","summary":"Supernus Pharmaceuticals received FDA approval for a new indication for Oxtellar XR, expanding its use to include the treatment of a broader range of patients with epilepsy.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-04-07","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxQVWh1LXZQejkySmpfbmdEcEVkQm9YQUxRTjhXUXlBVEU4dWl0VUh0cVNCc0VoX25LYUNXVXlPdDl0TUNsX0dISzh0bjJEQlR4bDRaTE8tN0VkdGNGQWZURWUtdllpZUc5a25vUVFTN1djTkdDWEhyYThPanJpOFItVHFxck80WEFHT2pYY19pMmNTTUJSSUpFRXVaeXRhYTBNcGF5VGZ1MzRqUWlVSTlCM29hV0lvSG8xTHVQWVVacWo?oc=5","date":"2026-03-27","type":"pipeline","source":"The Motley Fool","summary":"Supernus Pharma Insider Sells $5.4 Million as Stock Surges 53% in a Year - The Motley Fool","headline":"Supernus Pharma Insider Sells $5.4 Million as Stock Surges 53% in a Year","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-01","type":"pipeline","source":"simplywall.st","summary":"Supernus Pharmaceuticals (SUPN) Is Up 7.6% After Record Sales But 2025 Net Loss And Cautious 2026 Outlook - simplywall.st","headline":"Supernus Pharmaceuticals (SUPN) Is Up 7.6% After Record Sales But 2025 Net Loss And Cautious 2026 Outlook","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-26","type":"earnings","source":"simplywall.st","summary":"Supernus Pharmaceuticals (SUPN) Returns To Quarterly EPS Loss Reinforcing Profitability Concerns - simplywall.st","headline":"Supernus Pharmaceuticals (SUPN) Returns To Quarterly EPS Loss Reinforcing Profitability Concerns","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxOQXdlMUJ2ZWhEMjZCTEdFVWozalIydzAzVTFPYS1LVjRacThacDBUUFFfQkVwMUNhSVE2cEZySm5sbnNHLWhCZHFkbndmWEhvWF9LTXd1VWdjdHh5TkNQeXFjUGh1ZUNnWGFJM00yRGN4cElaNENGNFRQMDRzSWxaeTZuVjFHRE5IRHdfWFBwWDZVY1g1Tk1RdGJTOFlySlRtc0tHbVBwYUVYRGwyb0sxNUEyeWN3Mk82UTVQMmFPVQ?oc=5","date":"2026-02-24","type":"earnings","source":"TradingView","summary":"Supernus Pharmaceuticals’s (NASDAQ:SUPN) Q4 CY2025: Strong Sales - TradingView","headline":"Supernus Pharmaceuticals’s (NASDAQ:SUPN) Q4 CY2025: Strong Sales","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxNa01Pam1aeUhlbHpyeG5JTjdRcXpIN2VRdjhHdk5oX0VaTDFGSjU4NFh4M1lXcUx3WEI2WFhMS21yTkd6YTRtYUNHc0Zlejc4MThpYmZRT0xtNnJkaThtT1BtRVgxOGc1b1g2UVlzWXNBU0JhTWt3ZXpIRmZOSWFXdEhPNTh4VDRhQkVKMWk2YmlIVW01b0U4YmNlblExUHRpaWNDcTdRclZVeHRnZHdRLTBYc1Y4X09kbVpBQWdSeDJtN2RYLUZQUEpQQ3ctanZTVlhMaXlWb2Y?oc=5","date":"2026-02-22","type":"earnings","source":"TradingView","summary":"Supernus Pharmaceuticals (SUPN) To Report Earnings Tomorrow: Here Is What To Expect - TradingView","headline":"Supernus Pharmaceuticals (SUPN) To Report Earnings Tomorrow: Here Is What To Expect","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxPUFprMEM1RlJGMDdPQzNXX1MtVzN3dXY5bnNJQVlkdHlUZ3pLMUR6MS1jTTVvVlRTZV9nbi1teFpCU2h6Yk1jYnpJVy1ZRDdaSW9DalNoUzBsbEtDOEpvZHJRXzVjUV9OQ3Q3ZGpRdmZUTzBPLVVBTXF1cE9QMm5NQm1uZ214amRRUlJHZGRGc2MtSlhYbVFN?oc=5","date":"2026-02-17","type":"earnings","source":"Yahoo Finance","summary":"Earnings Preview: Supernus Pharmaceuticals (SUPN) Q4 Earnings Expected to Decline - Yahoo Finance","headline":"Earnings Preview: Supernus Pharmaceuticals (SUPN) Q4 Earnings Expected to Decline","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNamdEeHZkVG8yV3hHWktDYVN5aWtfLWVyWFNzMlBBTkRJNUhJZ0g2SEU5VTFHQmI0MFZiYm5RSmxjUU1peDdxYTV6TmkzX29HcUZTUy1rMmlTUmhkWVVkSUJDVmkyeEdQbUxvcURLWXpxb3FHV0R5OHJQdzBPSm5iTVRxem9Dd0xudV94ZElTeXBfZ1FmSnFhNzdqUmpmdm5vNGRoNzhwOXVfQ0w4QzVweEpINnJ4WHJD?oc=5","date":"2025-12-03","type":"pipeline","source":"Stock Titan","summary":"Supernus Pharmaceuticals (Nasdaq: SUPN) to present at Bank of America 2025 CNS Therapeutics Virtual Conference - Stock Titan","headline":"Supernus Pharmaceuticals (Nasdaq: SUPN) to present at Bank of America 2025 CNS Therapeutics Virtual Conference","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxOTWVXZDd6OXhZeW9BU3lBX3ZkOThIQmJnNW5ZM0VHTExGLUttVHFDT21Ca2FHd0xSVndncWhvb1R4UHRwbEd0b21XQVVULWQzVFFWallIODcwaWZ1ZllyeHhDMVRrNXU4RTkzLWtnY1VZOERUZlN6eEg5TDNLN1phdmVRNG1TSVI0M0dONFJYcng1RFlvcmZDNlA0OE5tSlFsdVZhSDNXT2k2dklEREViSTl1SXJLM0VjOVpv?oc=5","date":"2025-11-04","type":"earnings","source":"StockStory","summary":"Supernus Pharmaceuticals (NASDAQ:SUPN) Surprises With Strong Q3 - StockStory","headline":"Supernus Pharmaceuticals (NASDAQ:SUPN) Surprises With Strong Q3","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxNamdHb2Fna0czcW5JOWhuTThPaGZEb256dmI1a24ycXY3MnN2MGoyVk5zeGVKQXZqRjZDclRCazNQeUptZThsZV9mMVVVY25vOVppRnpSa0V5b2MxNHlscFhsU0JraFNaWEE4Y3hsQkxUbmdzRG5iT0lvM2lXYTV0Y2x1TFhKeGxab0NKajAxZ0pfWi1BNnhiVGdlX01MTzlXOWNpeFpmbEhmSnNrcHRheUxFZHhEbUVEQ0NZaUNrOFo1emtHRDg4TzdVdEp4UQ?oc=5","date":"2025-06-16","type":"deal","source":"Reuters","summary":"Supernus enters depression drug market with up to $795 million Sage deal - Reuters","headline":"Supernus enters depression drug market with up to $795 million Sage deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxQa2RyUW0zSl9ESlhnUFZqamtfeUV2T0tuc3k4d05zQndWTEtya3dMMWt5Qzk2NDhvX0Fidl9BZGk3QWpNdTY0aVRHM2JNTTZWdHpWdkJvU2FhaVg3LUh5Nlo4dkllMHlGRXFlb2pWQ1gwWW1KZFM2OTE1Y3RfOXBjUmQ1S2pQV3pJNmMxNWdUdkNkT1k0NG5sN3ln?oc=5","date":"2025-06-16","type":"pipeline","source":"Investor's Business Daily","summary":"Beleaguered Biotech Snapped Up In $561 Million Bid - Investor's Business Daily","headline":"Beleaguered Biotech Snapped Up In $561 Million Bid - Investor's Business Daily","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxPeFFhZGEzYTNjXzhFQjZsODVUOFJwQVpOaUs0OVpfemt4OW9DUWY0cVBOc1JHd05tNTZwUVlEQlJsV1Jicnhvd1duQUtCdDRmaElzZWF5X0RRYmdZY0ZfeFcwSkxFNGlmanJsUk1JdnA1ampiQzRkU3Zvd0NWVkVmX1dwUnlkb3FHSUxaVGxfVUYxRkdHa05TN05xdXBFb2I0T3M2N2VfTVhaeEU?oc=5","date":"2025-06-16","type":"deal","source":"Seeking Alpha","summary":"Supernus To Acquire Sage: A Smart Move, Despite Both Pharmas' MDD Woes (NASDAQ:SUPN) - Seeking Alpha","headline":"Supernus To Acquire Sage: A Smart Move, Despite Both Pharmas' MDD Woes (NASDAQ:SUPN)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgJBVV95cUxNeWxzZXRrcVFKTXJ3M0ptUWNrbWhyRDhXS081TTNFUnpPQmc4YktkRS03R1NsR3EtYVJIWHlpMGdWYlo2Z21sQ2JBWUNFWTVUdkZ1RE9yXy0xSExuZTFvUFZXSTRCYUhYTUJaUUJJZGJIRFdWajVpV0Q5QVo1SDdxMDNzUV9Md0x5aUNvZGhhaU5rRWpVMl82RC0zcWJ1QmRUbnZ2UXNhY1FXeDFuYXVHbThoMWNETEYtMXhwVmhUeWdyLXJsSFgyM2d1RnpuTXFyaFZuRWVoZjlhVmNVb3JtLU85RHZxMGJQMlh4RFplR3NTOTFMeGI0X2NkNDNHNTRBSktmMnpTb1M4ZlZHZ2c?oc=5","date":"2025-06-16","type":"deal","source":"GlobeNewswire","summary":"Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio - GlobeNewswire","headline":"Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio","sentiment":"neutral"}],"patents":[{"drugName":"Oxtellar XR","drugSlug":"oxcarbazepine","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":143800000},{"drugName":"Trokendi XR","drugSlug":"topiramate","patentNumber":"","type":"Patent Cliff","expiryDate":"2035-06-01","territory":"US","annualRevenue":64400000.00000001}],"drugCount":10,"phaseCounts":{"phase_3":4,"marketed":5,"phase_1":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Eisai Co., Ltd.","UCB S.A.","Lundbeck A/S"],"therapeuticFocus":["Epilepsy","Attention Deficit Hyperactivity Disorder (ADHD)"],"financials":{"source":"sec_edgar+yahoo","revenue":392755000,"revenuePeriod":"2019-12-31","revenueHistory":[{"value":392755000,"period":"2019-12-31"},{"value":100446000,"period":"2019-12-31"},{"value":102140000,"period":"2019-09-30"},{"value":104695000,"period":"2019-06-30"},{"value":85474000,"period":"2019-03-31"}],"grossProfit":644390000,"grossProfitHistory":[{"period":"2025-12-31","value":644390000},{"period":"2024-12-31","value":583911000},{"period":"2023-12-31","value":523742000},{"period":"2022-12-31","value":580017000}],"rdSpend":106235000,"rdSpendHistory":[{"period":"2025-12-31","value":106235000},{"period":"2024-12-31","value":108796000},{"period":"2023-12-31","value":91593000},{"period":"2022-12-31","value":74552000}],"sgaSpend":485563000,"operatingIncome":-36864000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-36864000},{"period":"2024-12-31","value":75556000},{"period":"2023-12-31","value":13403000},{"period":"2022-12-31","value":45614000}],"netIncome":-38550000,"netIncomeHistory":[{"period":"2025-12-31","value":-38550000},{"period":"2024-12-31","value":73865000},{"period":"2023-12-31","value":1316000},{"period":"2022-12-31","value":60711000}],"eps":-0.68,"epsHistory":[{"period":"2025-12-31","value":-0.68},{"period":"2024-12-31","value":1.32},{"period":"2023-12-31","value":0.02},{"period":"2022-12-31","value":1.04}],"cash":128448000,"cashHistory":[{"period":"2025-12-31","value":128448000},{"period":"2024-12-31","value":69331000},{"period":"2023-12-31","value":75054000},{"period":"2022-12-31","value":93120000}],"totalAssets":1452648000,"totalLiabilities":390934000,"totalDebt":40977000,"equity":1061714000,"operatingCashflow":47331000,"operatingCashflowHistory":[{"period":"2025-12-31","value":47331000},{"period":"2024-12-31","value":171951000},{"period":"2023-12-31","value":111085000},{"period":"2022-12-31","value":116826000}],"capex":-1338000,"capexHistory":[{"period":"2025-12-31","value":-1338000},{"period":"2024-12-31","value":-725000},{"period":"2023-12-31","value":-551000},{"period":"2022-12-31","value":-412000}],"freeCashflow":45993000,"dividendsPaid":null,"buybacks":null,"employees":778,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":122390000,"ebit":1656000,"ebitda":26672000,"period":"2025-12-31","revenue":211572000,"epsBasic":-0.07,"netIncome":-4105000,"rdExpense":27827000,"epsDiluted":-0.07,"grossProfit":188565000,"operatingIncome":13822000},{"sga":179678000,"ebit":-60231000,"ebitda":-35425000,"period":"2025-09-30","revenue":192103000,"epsBasic":-0.8,"netIncome":-45117000,"rdExpense":29366000,"epsDiluted":-0.8,"grossProfit":173138000,"operatingIncome":-60231000},{"sga":93551000,"ebit":12141000,"ebitda":33499000,"period":"2025-06-30","revenue":165453000,"epsBasic":0.4,"netIncome":22499000,"rdExpense":22115000,"epsDiluted":0.4,"grossProfit":148626000,"operatingIncome":12141000},{"sga":89944000,"ebit":-2596000,"ebitda":17787000,"period":"2025-03-31","revenue":149824000,"epsBasic":-0.21,"netIncome":-11827000,"rdExpense":26927000,"epsDiluted":-0.21,"grossProfit":134061000,"operatingIncome":-2596000},{"sga":79409000,"ebit":26382000,"ebitda":45227000,"period":"2024-12-31","revenue":174159000,"epsBasic":0.28,"netIncome":15328000,"rdExpense":28647000,"epsDiluted":0.27,"grossProfit":148061000,"operatingIncome":21761000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":51.13,"previousClose":51.36,"fiftyTwoWeekHigh":59.68,"fiftyTwoWeekLow":30.83,"fiftyTwoWeekRange":"30.83 - 59.68","fiftyDayAverage":50.55,"twoHundredDayAverage":48.39,"beta":0.57,"enterpriseValue":2637582080,"forwardPE":11.7,"priceToBook":2.77,"priceToSales":3.82,"enterpriseToRevenue":3.4,"enterpriseToEbitda":21.51,"pegRatio":0,"ebitda":122628000,"ebitdaMargin":15.8,"freeCashflow":132620496,"operatingCashflow":83256000,"totalDebt":40903000,"debtToEquity":3.8,"currentRatio":1.96,"returnOnAssets":1.1,"returnOnEquity":-2.8,"analystRating":"1.5 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":6,"targetMeanPrice":62.83,"targetHighPrice":66,"targetLowPrice":55,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":4.5,"institutionHeldPercent":103.1,"sharesOutstanding":58039721,"floatShares":52247357,"sharesShort":4721234,"shortRatio":8.86,"shortPercentOfFloat":8.1,"epsTrailing":-0.51,"epsForward":4.37,"revenuePerShare":13.65,"bookValue":18.48,"officers":[{"age":64,"name":"Mr. Jack A. Khattar M.B.A.","title":"Founder, President, CEO, Secretary & Director"},{"age":66,"name":"Mr. Timothy C. Dec","title":"Senior VP & CFO"},{"age":68,"name":"Dr. Padmanabh P. Bhatt Ph.D.","title":"Chief Scientific Officer & Senior VP of Intellectual Property"},{"age":53,"name":"Mr. Frank  Mottola","title":"Senior VP & Chief Technology Operations Officer"},{"age":64,"name":"Dr. Jonathan  Rubin M.B.A., M.D.","title":"Senior VP of Research & Development and Chief Medical Officer"},{"age":63,"name":"Mr. Kevin T. Anderson Esq.","title":"Compliance Officer"},{"age":null,"name":"Mr. Taylor  Raiford","title":"Senior Vice President of Sales"},{"age":52,"name":"Dr. William Todd Horich M.B.A., Ph.D.","title":"Senior VP & Chief Commercial Officer"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"","website":"https://www.supernus.com","phone":"301 838 2500"}}